combining glp-1 receptor agonist with dpp-4 inhibitor not recommended guideline versus and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes do not combine dpp-4 inhibitors
Description
The reference lists of all publications were queried to detect studies not identified during the initial search
Two major analytical methods LBA and LC-MS/MS are used for PK studies, each with strengths and challenges
Systemic administration of anorexic gut peptide hormones impairs hedonic-driven sucrose consumption in mice
All GLP-1 medications have been proven to be effective for diabetes, and some have been studied and proven to be effective for weight loss as well
Read this first
doi: 10.1016/s0014-2999(01)01542-4
